BRAF and Langerhans cell histiocytosis: Nearly all LCH lesions carry recurrent mutations in the mitogen-activated protein kinase (MAPK) pathway, with 50% of patients carrying BRAF mutations and 25% bearing MAP2K1 mutations [4].